Repository logo
 
Publication

Population homogeneity for the antibody response to COVID-19 BNT162b2/Comirnaty vaccine is only reached after the second dose across all adult age ranges

2022-01-10Journal article Open access
Simple item page
dc.contributor.authorFaro-Viana, João
dc.contributor.authorBergman, Marie-Louise
dc.contributor.authorGonçalves, Lígia A.
dc.contributor.authorDuarte, Nadia
dc.contributor.authorCoutinho, Teresa P.
dc.contributor.authorBorges, Patricia C.
dc.contributor.authorDiwo, Christian
dc.contributor.authorCastro, Rute
dc.contributor.author...
dc.contributor.authorNunes, Telmo
dc.contributor.authoret al.
dc.date.accessioned2022-07-11T17:06:22Z
dc.date.available2022-07-11T17:06:22Z
dc.date.issued2022-01-10
dc.description.abstractABSTRACT: While mRNA vaccines are administrated worldwide in an effort to contain the COVID-19 pandemic, the heterogeneity of the humoral immune response they induce at the population scale remains unclear. Here, in a prospective, longitudinal, cohort-study, including 1245 hospital care workers and 146 nursing home residents scheduled for BNT162b2 vaccination, together covering adult ages from 19 to 99 years, we analyse seroconversion to SARS-CoV-2 spike protein and amount of spike-specific IgG, IgM and IgA before vaccination, and 3-5 weeks after each dose. We show that immunogenicity after a single vaccine dose is biased to IgG, heterogeneous and reduced with increasing age. The second vaccine dose normalizes IgG seroconversion in all age strata. These findings indicate two dose mRNA vaccines is required to reach population scale humoral immunity. The results advocate for the interval between the two doses not to be extended, and for serological monitoring of elderly and immunosuppressed vaccinees.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationFaro-Viana J, Bergman ML, Gonçalves LA, Duarte N, Coutinho TP, Borges PC, Diwo C, Castro R, Matoso P, Malheiro V [et al.]. 2022. Population homogeneity for the antibody response to COVID-19 BNT162b2/Comirnaty vaccine is only reached after the second dose across all adult age ranges. Nature Communications, 13(1):140. DOI: https://doi.org/10.1038/s41467-021-27761-zpt_PT
dc.identifier.doihttps://doi.org/10.1038/s41467-021-27761-zpt_PT
dc.identifier.eissn2041-1723
dc.identifier.urihttp://hdl.handle.net/10400.5/24815
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherNature Researchpt_PT
dc.relation.publisherversionhttps://www.nature.com/articles/s41467-021-27761-zpt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectAntibody responsept_PT
dc.subjectCOVID-19pt_PT
dc.subjectBNT162b2/Comirnaty vaccinept_PT
dc.titlePopulation homogeneity for the antibody response to COVID-19 BNT162b2/Comirnaty vaccine is only reached after the second dose across all adult age rangespt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.titleNature Communicationspt_PT
oaire.citation.volume13(1):140pt_PT
person.familyNameLandeiro Raposo Pina Nunes
person.givenNameTelmo Renato
person.identifier.ciencia-id2C1A-E281-3E6F
person.identifier.orcid0000-0003-4388-5366
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicationacbacc01-80c6-4ac1-9eab-ce8daa65442c
relation.isAuthorOfPublication.latestForDiscoveryacbacc01-80c6-4ac1-9eab-ce8daa65442c

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Population homogeneity for the antibody response to COVID-19 BNT162b2_Comirnaty vaccine is only reached after the second dose across all adult age ranges.pdf
Size:
3.13 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

CIISA - Artigos em revistas internacionais